Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
50 hedge funds and large institutions have $379M invested in Tourmaline Bio in 2021 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
62.89% more ownership
Funds ownership: 0% → 62.89% (+63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$124M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$50.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$40.9M |
| 4 |
AG
Artal Group
Luxembourg
|
+$31.6M |
| 5 |
BlackRock
New York
|
+$27.2M |
Top Sellers
TRML Hedge Fund Activity: Q2 2021 in Review
50 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q2 2021, worth a combined $379M.
Buyers outnumbered sellers: 50 funds opened new TRML positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Blackstone Inc, opening a new position worth an estimated $124M.
- 50 institutional investors held Tourmaline Bio (TRML) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $379M of Tourmaline Bio stock for Q2 2021.
- 50 funds opened new Tourmaline Bio positions in Q2 2021 and 0 closed out, a net change of +50 holders.
- The largest Tourmaline Bio buyer in Q2 2021 was Blackstone Inc, an estimated $124M added.
Based on aggregated 13F filings for Q2 2021.